Anthony Ocon is a Rheumatology/Immunology physician affiliated with University of Rochester Medical Center. OpenAlex indexes 52 publications with 1,279 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
12 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.4%Folate Analog Metabolic Inhibitor12.3%Methotrexate100%Part D≥81 patientsNonsteroidal Anti-inflammatory Drug9.1%Celecoxib100%Part D≥59 patients+ 7 more classes in this area
Antiparasitic
22.1%Antimalarial22.1%Hydroxychloroquine Sulfate100%Part D≥105 patientsMetabolism & gastrointestinal
18.2%Corticosteroid13.8%Prednisone100%Part D≥106 patientsAntidiarrheal microorganisms2.4%Folic Acid100%Part D≥20 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2009–2012 per NIH RePORTER. The latest:
- Inhibition of NO Dependent Splanchnic Hyperemia Improves CFS/POTS
New York Medical College
FY2012$42,628F30HL097380 - Inhibition of NO Dependent Splanchnic Hyperemia Improves CFS/POTS
New York Medical College
FY2011$46,800F30HL097380 - Inhibition of NO Dependent Splanchnic Hyperemia Improves CFS/POTS
New York Medical College
FY2010$27,988F30HL097380
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ann Falsey, MD
University of Rochester Medical Center
Louis Constine, MD
University of Rochester Medical Center
Supriya Mohile, MD
University of Rochester Medical Center
Paul Barr, MD
University of Rochester Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”